Protocol Ledger

NCT05621317 · Phase II · ACTIVE NOT RECRUITING

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Interventional Phase II clinical trial protocol NCT05621317 sponsored by Aravax Pty in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-09 Enrollment: 95 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05621317
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)95 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05621317
Protocol FieldVerified Registry Value
NCT IdentifierNCT05621317
Consolidated Lead SponsorAravax Pty
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment95 participants (ACTUAL)
Registered Start Date2023-02-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI